guest ::
| Home > Publications Database > New trends in pharmacological control of neuropsychiatric symptoms of dementia. |
| Home > Publications Database > New trends in pharmacological control of neuropsychiatric symptoms of dementia. |
| Journal Article (Review Article) | DZNE-2022-00141 |
; ; ; ;
2021
Elsevier Science
Amsterdam [u.a.]
This record in other databases: 
Please use a persistent id in citations: doi:10.1016/j.coph.2021.09.002
Abstract: Abnormal neuronal and synaptic plasticity occurs in Alzheimer's disease (AD) and depression. The latter, particularly late-life, has been recognized as fundamental in the identification of at-risk prodromal stages of AD. The lack of disease-modifying drugs and the off-label use of antipsychotics and antidepressants for neuropsychiatric symptoms (NPSs) have caused a season of therapeutic inappropriateness. To date, the wealth of clinical trials investigating drugs, diverse for structure and mechanism of action, has failed to provide a cure for all the spectrums of NPSs. Psychedelics in microdosing afford promotion of neurogenesis and synaptic plasticity and, recently, have been considered a revolution for the management of depression endowed with faster action and an improved side effect profile than antidepressants. In the current scenario, therefore, the rapid-acting antidepressant esketamine could represent the first-in-class for treatment of NPSs, and this deserves to be demonstrated with an open-label clinical trial.
Keyword(s): Alzheimer Disease: drug therapy (MeSH) ; Antidepressive Agents: adverse effects (MeSH) ; Antipsychotic Agents: adverse effects (MeSH) ; Humans (MeSH) ; Antidepressive Agents ; Antipsychotic Agents
; 
; 
; BIOSIS Previews ; BIOSIS Reviews Reports And Meetings ; Clarivate Analytics Master Journal List ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
PDF
PDF (PDFA)